From Breakthrough to Access: How Biotechnology and Artificial Intelligence are Reshaping the Scalability and Precision of Cancer Immunotherapy

نویسندگان
doi
چکیده

Over the past decade, cancer immunotherapy has transformed oncology, enabling durable responses in previously intractable malignancies. Immune checkpoint inhibitors (ICIs), adoptive cell therapies, and related strategies have demonstrated the power of harnessing the immune system to eliminate cancer. However, benefits remain uneven; many patients fail to respond or develop resistance (2-4). The field now stands at a critical inflection point where incremental improvements to existing platforms may yield diminishing returns unless they directly address resistance mechanisms. These include T-cell dysfunction, antigen loss, impaired antigen presentation, and immunosuppressive signaling within the tumor microenvironment (TME). Cancer immunotherapy is at a turning point defined by integration, precision, and strategic prioritization. The challenge is no longer to demonstrate efficacy, but to achieve consistent, durable, and accessible responses. Biotechnology plays a key role in this journey, with an expanding arsenal ranging from engineered ICIs and TILs to CRISPR-enhanced cell therapies. Progress will be driven by advanced drug delivery systems (lipid/polymer nanoparticles) and synthetic biology for “smarter” immune cells. Reengineering access to immune responses and leveraging the convergence of bioengineering and AI will be critical. Ultimately, the future of oncology hinges on our ability to translate high-dimensional biological data into precise, adaptive, and accessible clinical solutions.